Alzheimer's is a serious brain disease affecting many people. New treatments called anti-amyloid monoclonal antibodies (mAbs) like lecanemab and donanemab, approved by the FDA, are being studied to see how well they work. The Georgia Memory Net (GMN) is collecting information on patients using these treatments. This will help doctors understand the benefits and risks like brain swelling or bleeding. The registry is for people aged 50-90 with mild memory problems. Participation involves regular check-ups and tests, including MRI scans. This study may last as long as the treatment is needed, but the exact time is not specified.
- Participants must be aged 50-90 and have mild cognitive impairment.
- Regular visits and tests are required, including MRIs and cognitive tests.
- Patients need a caregiver to attend follow-ups and provide information.